Key Highlights: Implications: Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic...
Key Highlights: Implications: Sun ignites generics price war against Novo/Eli Lilly premium brands, slashing obesity therapy costs and exploding Tier-2/3 access. Dual T2D/weight...
